Corporate StrategyMindWalk Patents AI Data Layer as Novo Nordisk Pivots to Licensed ManufacturingSalvado•Aug 1, 2026
Pharma StrategyNovo Nordisk Shuts Internal Cell Therapy Unit, Licenses Parkinson's Asset to AI Platform as Stock Gains 24.9%Salvado•Jul 23, 2026
Corporate StrategyNovo Nordisk Closes Internal Cell Therapy Unit, Licenses Program to AI-Native Cellular IntelligenceSalvado•May 21, 2026
Corporate Strategy & Business TransformationNovo Nordisk's 25% Stock Surge Validates Pharma's Pivot to AI Platform OutsourcingSalvado•May 18, 2026
